Alliances
Thermo Fisher Scientific has launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as it engages in more large-scale cohort studies and clinical research.
The vaccine candidate ASP3772 generated an antibody response to each of the 24 polysaccharides in its makeup and antibody response to the two conserved pneumococcal proteins.
The license and collaboration agreement center on orelabrutinib, an oral small molecule BTKi characterized by its high selectivity and the ability to cross the blood-brain barrier.
Startups have passion and big, bold ideas. Pharma has the funds and human resources. Together, they can change the future of medicine.
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
This morning, multiple companies announced clinical and strategic collaborations to develop novel therapies and treatments for various diseases. Here are some of them.
Arbutus Biopharma forged a clinical collaboration with U.K.-based Vaccitech plc to develop a new treatment for people infected with chronic hepatitis B virus who are already receiving standard-of--care therapy.
The two antibody candidates, AL001 and AL101, are seen as potential first-in-class medications aimed at a range of neurodegenerative diseases.
NGM Biopharmaceuticals and Merck announced they had amended their existing collaboration agreement. It will continue through March 2024, but have a narrower scope.
Seres Therapeutics and Nestlé Health Science have announced a decision to team up for the joint commercialization of Seres’s investigational oral microbiome treatment for recurrent Clostridioides difficile infections.
PRESS RELEASES